These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 20561096)

  • 1. Management of gout: beyond allopurinol.
    McGill NW
    Intern Med J; 2010 Aug; 40(8):545-53. PubMed ID: 20561096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical inquiry. Are serum uric acid levels always elevated in acute gout?
    Leiszler M; Poddar S; Fletcher A
    J Fam Pract; 2011 Oct; 60(10):618-20. PubMed ID: 21977490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Inhibition of endogenous synthesis of uric acid with allopurinol in patients with gout and urate diathesis].
    Holländer E; Schwarczmann P
    Munch Med Wochenschr; 1969 Aug; 111(32):1623-6. PubMed ID: 5394966
    [No Abstract]   [Full Text] [Related]  

  • 4. [The effect of daily single doses of 300 mg allopurinol on serum uric acid concentration and urate excretion in gouty patients (author's transl)].
    Matzkies F; Berg G
    Dtsch Med Wochenschr; 1974 Nov; 99(48):2464-5. PubMed ID: 4448143
    [No Abstract]   [Full Text] [Related]  

  • 5. The current state of care in gout: Addressing the need for better understanding of an ancient disease.
    Zychowicz ME; Pope RS; Graser E
    J Am Acad Nurse Pract; 2010 Nov; 22 Suppl 1():623-36. PubMed ID: 21054636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
    Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
    Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?
    Li-Yu J; Clayburne G; Sieck M; Beutler A; Rull M; Eisner E; Schumacher HR
    J Rheumatol; 2001 Mar; 28(3):577-80. PubMed ID: 11296962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous measurement of plasma and erythrocyte oxypurines. II. Gouty patients with and without allopurinol medication.
    Hayashi TT; Gillo D; Turner JH; Rodnan GP
    Gynecol Invest; 1972; 3(5):221-36. PubMed ID: 4656975
    [No Abstract]   [Full Text] [Related]  

  • 9. Gout--what are the treatment options?
    Schlesinger N; Dalbeth N; Perez-Ruiz F
    Expert Opin Pharmacother; 2009 Jun; 10(8):1319-28. PubMed ID: 19463070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
    Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
    Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
    Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gout and hyperuricemia.
    Harris MD; Siegel LB; Alloway JA
    Am Fam Physician; 1999 Feb; 59(4):925-34. PubMed ID: 10068714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hyperuricemia and gout: therapeutic indications].
    Pawlotsky Y
    Rev Prat; 1994 Jan; 44(2):206-9. PubMed ID: 8178077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?
    Perez-Ruiz F; Lioté F
    Arthritis Rheum; 2007 Oct; 57(7):1324-8. PubMed ID: 17907217
    [No Abstract]   [Full Text] [Related]  

  • 17. [Allopurinol and gouty hyperuricemia : apropos of 30 cases treated by a single daily dose].
    Appelboom T; Famaey JP
    Brux Med; 1977 Mar; 57(3):133-7. PubMed ID: 861817
    [No Abstract]   [Full Text] [Related]  

  • 18. Opportunities for improving medication use and monitoring in gout.
    Singh JA; Hodges JS; Asch SM
    Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the urate lowering effects of allopurinol and diflunisal.
    Emmerson BT; Hazelton RA; Whyte IM
    J Rheumatol; 1987 Apr; 14(2):335-7. PubMed ID: 3599002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical findings and therapy of gout with special reference to the metabolic effects of sulfinpyrazone (Anturan) and allopurinol (Zyloric)].
    Günther R; Knapp E
    Wien Klin Wochenschr; 1969 Nov; 81(45):817-20. PubMed ID: 5362152
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.